Valcyte Related Published Studies
Well-designed clinical trials related to Valcyte (Valganciclovir)
Long-term efficacy and safety of 12 months of valganciclovir prophylaxis compared with 3 months after lung transplantation: a single-center, long-term follow-up analysis from a randomized, controlled cytomegalovirus prevention trial. [2011.09]
Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy. [2011.05.15]
Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study. [2010.12.27]
Ganciclovir pharmacokinetic parameters do not change when extending valganciclovir cytomegalovirus prophylaxis from 100 to 200 days. [2010.12.27]
Impact of prophylactic versus preemptive valganciclovir on long-term renal allograft outcomes. [2010.08.27]
Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial. [2010.06.15]
The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. [2010.05]
Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung
transplantation: a randomized, controlled trial. [2010]
Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. [2009.05]
Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir. [2009]
Valganciclovir for suppression of human herpesvirus-8 replication: a randomized, double-blind, placebo-controlled, crossover trial. [2008.07.01]
Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. [2008.01]
Pharmacokinetics of ganciclovir after oral valganciclovir versus intravenous ganciclovir in allogeneic stem cell transplant patients with graft-versus-host disease of the gastrointestinal tract. [2006.06]
Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation. [2006.04.01]
Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. [2005.06.15]
Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients. [2005]
Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. [2004.05.01]
Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. [2004.04]
A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. [2002.04.11]
Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis. [2001.12.15]
Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. [2000.10]
Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects. [1999.08]
Well-designed clinical trials possibly related to Valcyte (Valganciclovir)
Cytomegalovirus. [2014]
Viral factors influencing the outcome of human cytomegalovirus infection in liver transplant recipients. [2011.08]
Adaptive seamless design for an efficacy trial of replication-competent adenovirus-mediated suicide gene therapy and radiation in newly-diagnosed prostate cancer (ReCAP Trial). [2011.05]
Effects of the intensity of immunosuppressive therapy on outcome of treatment for CMV disease in organ transplant recipients. [2010.08]
Intragraft cytomegalovirus infection: a randomized trial of valacyclovir prophylaxis versus pre-emptive therapy in renal transplant recipients. [2010]
Antiviral agents for treatment of herpes simplex virus infection in neonates. [2009.07.08]
Low rate of CMV end-organ disease in HIV-infected patients despite low CD4+ cell counts and CMV viremia: results of ACTG protocol A5030. [2009.05]
Treatment of congenital cytomegalovirus infection: implications for future therapeutic strategies. [2009.05]
An assessment of herpesvirus co-infections in patients with CMV disease: correlation with clinical and virologic outcomes. [2009.02]
Cytomegalovirus infection after liver transplantation: current concepts and challenges. [2008.08.21]
Oral valgancyclovir versus intravenous gancyclovir for cytomegalovirus prophylaxis in kidney transplant recipients. [2007.05]
Reactivation of viruses in solid organ transplant patients receiving cytomegalovirus prophylaxis. [2006.07.27]
A surveillance study of adenovirus infection in adult solid organ transplant recipients. [2005.10]
Clinical impact of ganciclovir-resistant cytomegalovirus infections in solid organ transplant patients. [2005.09]
Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R- transplant recipients. [2005.05]
Risk factors for cytomegalovirus viremia and disease developing after prophylaxis in high-risk solid-organ transplant recipients. [2004.12.27]
Clinical utility of cytomegalovirus viral load testing for predicting CMV disease in D+/R- solid organ transplant recipients. [2004.04]
Other research related to Valcyte (Valganciclovir)
Critical analysis of valganciclovir dosing and renal function on the development
of cytomegalovirus infection in kidney transplantation. [2013]
[The evaluation of cost-effectiveness and cost-utility of valganciclovir for the
prophylaxis of cytomegalovirus disease to 200 days after kidney transplantation]. [Article in Polish] [2013]
Long-term outcomes of pre-emptive valganciclovir compared with valacyclovir
prophylaxis for prevention of cytomegalovirus in renal transplantation. [2012]
Evaluation of valganciclovir pharmacokinetics in lung transplant recipients. [2012]
Oral valganciclovir versus ganciclovir as delayed pre-emptive therapy for
patients after allogeneic hematopoietic stem cell transplant: a pilot trial
(04-0274) and review of the literature. [2012]
Valganciclovir Prophylaxis Versus Preemptive Therapy in Cytomegalovirus-Positive Renal Allograft Recipients: 1-Year Results of a Randomized Clinical Trial. [2011.11.16]
Valganciclovir to prevent or treat cytomegalovirus disease in organ transplantation. [2011.11]
Oral valganciclovir versus ganciclovir as delayed pre-emptive therapy for patients after allogeneic hematopoietic stem cell transplant: a pilot trial (04-0274) and review of the literature. [2011.10.28]
Oral valganciclovir versus intravenous ganciclovir as preemptive treatment for cytomegalovirus infection after living donor liver transplantation: A randomized trial. [2011.10]
Successful corneal autograft after clearance of anterior chamber cytomegalovirus with oral valganciclovir in a patient with multiple failed corneal allografts. [2011.09]
Determination of valganciclovir and ganciclovir in human plasma by liquid chromatography tandem mass spectrometric detection. [2011.07]
High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy. [2011.06.30]
Pilot study of oral valganciclovir therapy in patients with classic Kaposi sarcoma. [2011.04.15]
Polyfunctional cytomegalovirus-specific immunity in lung transplant recipients receiving valganciclovir prophylaxis. [2011.03]
Effectiveness of valganciclovir 900 mg versus 450 mg for cytomegalovirus prophylaxis in transplantation: direct and indirect treatment comparison meta-analysis. [2011.02.01]
Impact of a preemptive strategy after 3 months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients. [2011.01.27]
24 weeks of valganciclovir prophylaxis in children after renal transplantation: a 4-year experience. [2011.01.27]
Post-liver transplantation multicentric Castleman disease treated with valganciclovir and weaning of immunosuppression. [2011.01]
Oral valganciclovir versus intravenous ganciclovir as preemptive treatment for
cytomegalovirus infection after living donor liver transplantation: a randomized
trial. [2011]
Valganciclovir to prevent or treat cytomegalovirus disease in organ
transplantation. [2011]
Valganciclovir reduces T cell activation in HIV-infected individuals with
incomplete CD4+ T cell recovery on antiretroviral therapy. [2011]
Valganciclovir is an effective prophylaxis for cytomegalovirus disease in liver transplant recipients. [2010.12]
Viral-associated trichodysplasia of immunosuppression: report of a pediatric patient with response to oral valganciclovir. [2010.08]
Valganciclovir: recent progress. [2010.06]
Sequential treatment of cytomegalovirus infection or disease with a short course of intravenous ganciclovir followed by oral valganciclovir: efficacy, safety, and pharmacokinetics. [2010.06]
Primary cytomegalovirus infectious colitis complicating Crohn's disease successfully treated with oral valganciclovir. [2010.06]
Valganciclovir for the prevention and treatment of CMV in solid organ transplant recipients. [2010.05]
Incidence and characterization of cytomegalovirus resistance mutations among pediatric solid organ transplant patients who received valganciclovir prophylaxis. [2010.04]
Intravitreal loading injection of ganciclovir with or without adjunctive oral valganciclovir for cytomegalovirus anterior uveitis. [2010.02]
Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D+/R- transplant recipients. [2010.01.06]
High efficacy and low toxicity of short-course oral valganciclovir as pre-emptive therapy for hematopoietic stem cell transplant cytomegalovirus infection. [2010]
Low-dose valganciclovir as preemptive therapy for cytomegalovirus infection occurring in allogeneic stem cell transplant recipients. [2010]
Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients is
associated with long-term reduction in cytomegalovirus disease: two-year results
of the IMPACT study. [2010]
Impact of prophylactic versus preemptive valganciclovir on long-term renal
allograft outcomes. [2010]
The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in
high-risk kidney transplant recipients. [2010]
Oral valganciclovir treatment in newborns with symptomatic congenital cytomegalovirus infection. [2009.12]
Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus. [2009.11]
Increased incidence of cytomegalovirus infection in high-risk liver transplant recipients receiving valganciclovir prophylaxis versus ganciclovir prophylaxis. [2009.08]
Cytomegalovirus prevention in high-risk lung transplant recipients: comparison of 3- vs 12-month valganciclovir therapy. [2009.07]
Severe bone marrow failure due to valganciclovir overdose after renal transplantation from cadaveric donors: four consecutive cases. [2009.06]
Incidence, risk factors, and outcome of cytomegalovirus infection and disease in patients receiving prophylaxis with oral valganciclovir or intravenous ganciclovir after umbilical cord blood transplantation. [2009.06]
[Prolonged treatment with valganciclovir in an infant with congenital cytomegalovirus infection] [2009.06]
A multicenter study of valganciclovir prophylaxis up to day 120 in CMV-seropositive lung transplant recipients. [2009.05]
Valganciclovir-induced leukopenia in liver transplant recipients: influence of concomitant use of mycophenolate mofetil. [2009.04]
Impact of valganciclovir on Epstein-Barr Virus polymerase chain reaction in pediatric liver transplantation: preliminary report. [2009.04]
Oral ganciclovir versus valganciclovir for cytomegalovirus prophylaxis in high-risk liver transplant recipients. [2009.04]
Valganciclovir dosing according to body surface area and renal function in pediatric solid organ transplant recipients. [2009.03]
Successful valganciclovir treatment of post-transplant cytomegalovirus infection in the presence of UL97 mutation N597D. [2009.03]
Oral valganciclovir as preemptive therapy is effective for cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients. [2009.03]
Valganciclovir as pre-emptive therapy for cytomegalovirus infection post-allogenic stem cell transplantation: implications for the emergence of drug-resistant cytomegalovirus. [2009.03]
Results of a phase I/II British Society of Bone Marrow Transplantation study on PCR-based pre-emptive therapy with valganciclovir or ganciclovir for active CMV infection following alemtuzumab-based reduced intensity allogeneic stem cell transplantation. [2009.02]
Resistance pattern of cytomegalovirus (CMV) after oral valganciclovir therapy in transplant recipients at high-risk for CMV infection. [2009.02]
Prospective follow-up of primary CMV infections after 6 months of valganciclovir prophylaxis in renal transplant recipients. [2009.01]
Human herpesvirus 6 meningoradiculitis treated with intravenous immunoglobulin and valganciclovir. [2009.01]
Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: an evidence-based reassessment of safety and efficacy. [2009]
Valganciclovir in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements. [2009]
Population pharmacokinetics of ganciclovir following administration of valganciclovir in paediatric renal transplant patients. [2009]
[Valganciclovir for treatment of cytomegalovirus viremia in patients following allogeneic hematopoietic stem cell transplantation] [2008.12.16]
Randomized prospective study of the evolution of renal function depending on the anticalcineurin used. [2008.11]
Prevention of posttransplant cytomegalovirus disease and related outcomes with valganciclovir: a systematic review. [2008.10]
Results of a phase I/II British Society of Bone Marrow Transplantation study on PCR-based pre-emptive therapy with valganciclovir or ganciclovir for active CMV infection following alemtuzumab-based reduced intensity allogeneic stem cell transplantation. [2008.09.19]
Selective low-dose valganciclovir for prevention of cytomegalovirus disease following kidney transplantation. [2008.09]
|